Subscribe

Articles

Biosimilars Year in Review Introduction
Biosimilars
2020 Year in Review - Biosimilars
Due to the COVID-19 pandemic, the year 2020 has witnessed unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums. Read More ›
Establishing Analytical and Clinical Similarity Between HD201 and Trastuzumab
Biosimilars
2020 Year in Review - Biosimilars
The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab. Read More ›
Population-Based, Real-World Data of Neoadjuvant Chemotherapy + Pertuzumab + SB3 in HER2-Positive, Early Breast Cancer
Biosimilars
2020 Year in Review - Biosimilars
Population-based study results support the use of the neoadjuvant chemotherapy + pertuzumab + trastuzumab biosimilar SB3 treatment regimen in the real-world setting, with responses comparable with those achieved in clinical trials. Read More ›
Metastatic Non–Small-Cell Lung Cancer
Metastatic Non–Small-Cell Lung Cancer
By David Spigel, MD
Lung Cancer
2020 Year in Review - Lung Cancer
Dr David Spigel reviews 5 practice-changing presentations from 2020 on the treatment of metastatic NSCLC using immunotherapy alone or in combination with chemotherapy or targeted agents. Read More ›
Nonmetastatic Non–Small-Cell Lung Cancer
Nonmetastatic Non–Small-Cell Lung Cancer
By Geoff Oxnard, MD
Lung Cancer
2020 Year in Review - Lung Cancer
Dr Geoff Oxnard outlines promising results from the key studies from 2020 on the neoadjuvant or adjuvant treatment of resectable and/or nonmetastatic NSCLC, as well as the value of stereotactic body radiotherapy in place of surgery during the COVID-19 pandemic. Read More ›
Small-Cell Lung Cancer and Mesothelioma
Small-Cell Lung Cancer and Mesothelioma
By David Spigel, MD
Lung Cancer
2020 Year in Review - Lung Cancer
Dr David Spigel reviews the results of key studies from 2020 on novel approaches to first- or second-line treatment of SCLC and mesothelioma with both existing and emerging agents. Read More ›
Metastatic Non–Small-Cell Lung Cancer with Targetable Mutations
Metastatic Non–Small-Cell Lung Cancer with Targetable Mutations
By Geoff Oxnard, MD
Lung Cancer
2020 Year in Review - Lung Cancer
Dr Geoff Oxnard provides an overview of novel approaches to metastatic NSCLC with targetable mutations, including established and newly discovered molecular targets. Read More ›
Comparison of Healthcare Resource Utilization and Costs in Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
Breast Cancer
2020 Year in Review - Breast Cancer
In this real-world setting study, similar healthcare costs and healthcare resource utilization among patients treated with ribociclib and palbociclib were observed. However, fewer inpatient days were experienced by patients treated with ribociclib when compared with abemaciclib. Read More ›
Incidence of Thrombotic Events with CDK4/6 Inhibitor Use in Real-World Practice Compared with Clinical Trial Settings
Breast Cancer
2020 Year in Review - Breast Cancer
Thrombotic event incidence was higher in this real-world study than that which was reported in clinical trials, with arterial thrombosis accounting for more than one-third of events. Read More ›

Page 94 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.